Biotechnology sector saw a surge in stocks on Wednesday following the Food and Drug Administration's announcement signaling the conclusion of a nerve-wracking journey for UniQure. This positive development had a notable impact on the market, with UniQure's stock experiencing a significant rise. The news not only boosted investor confidence in UniQure but also contributed to the overall optimism in the biotech industry. This upward trend reflects the promising future for UniQure and exemplifies the resilience and potential of biotech stocks in the current market climate.